AMRN
AMARIN CORP PLC\UK
- Latest sale
- $27k
- Dec 12 · Routine
- Form 4 sales
- 130
- On record
- Form 144 notices
- 1
- Proposed sales
- Next unlock
- None
- No lockup ahead
Lockups
No lockup on record.
Sales by reason
Timeline
- 1 Form 4 saleUnusualJan 3 2020
Sold 300,000 shares at $20.94 ($6.3M)
Zakrzewski Joseph S, Director
Sold 78% of holdings ($8.1M position)84,547 shares left1.7x usual sizeFiling
- 2 Form 4 salePlan not statedMar 4 +61 days
Sold 200,000 shares at $15.99 ($3.2M)
Thero John F, President and CEO
Sold 7.5% of holdings ($42.9M position)2.5M shares left0.5x usual sizeFiling
- 3 Form 4 salePlan not statedNov 11 +252 days
Sold 567,405 shares at $4.09 ($2.3M)
Thero John F, President and CEO
Sold 17.2% of holdings ($13.5M position)2.7M shares left2.1x usual sizeFiling
- 4 Form 4 saleUnusualJan 27 +77 days
Sold 421,629 shares at $8.01 ($3.4M)
Ketchum Steven B, Chief Scientific Officer
Sold 52.1% of holdings ($6.5M position)388,112 shares left17.9x usual sizeFiling
- 5 Form 4 saleUnusualFeb 1 +5 days
Sold 217,728 shares at $8.06 ($1.8M)
Ketchum Steven B, Chief Scientific Officer
Sold 36.2% of holdings ($4.8M position)382,996 shares left6.7x usual sizeFiling
- 6 Form 4 saleUnusualAug 12 +192 days
Sold 120,000 shares at $5.25 ($630k)
Kalb Michael Wayne, SVP and CFO
Sold 36.9% of holdings ($1.7M position)205,010 shares leftFiling
- 7 Form 144 noticeNoticeDec 12 +852 days
Filed to sell 34,131 shares ($29k)
Ketchum Steven B, Officer
10b5-1 planFirst sale on recordFiling
- 8 Form 4 saleRoutineDec 12 same day
Sold 34,131 shares at $0.79 ($27k)
Ketchum Steven B, Chief Scientific Officer
10b5-1 planSold 5.7% of holdings ($474k position)566,100 shares leftFirst sale on recordFiling
Every transaction
Loading transactions…
Sales, notices and lockups (131)
Export watchlist as CSV| Source | ||||||||
|---|---|---|---|---|---|---|---|---|
| Dec 12, 2023 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 34,131 | $27k | 5.7% | Routine | SEC |
| Dec 12, 2023 | Ketchum Steven B | Officer | Form 144 notice | 34,131 | $29k | Notice | SEC | |
| Aug 12, 2021 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 120,000 | $630k | 36.9% | Unusual | SEC |
| Feb 1, 2021 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 217,728 | $1.8M | 36.2% | Unusual | SEC |
| Jan 27, 2021 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 421,629 | $3.4M | 52.1% | Unusual | SEC |
| Nov 11, 2020 | Thero John F | President and CEO | Form 4 sale | 567,405 | $2.3M | 17.2% | Plan not stated | SEC |
| Mar 4, 2020 | Thero John F | President and CEO | Form 4 sale | 200,000 | $3.2M | 7.5% | Plan not stated | SEC |
| Jan 3, 2020 | Zakrzewski Joseph S | Director | Form 4 sale | 300,000 | $6.3M | 78.0% | Unusual | SEC |
| Dec 16, 2019 | Zakrzewski Joseph S | Director | Form 4 sale | 100,000 | $2.6M | 54.2% | Unusual | SEC |
| Dec 16, 2019 | Berg Aaron | CHIEF COMMERCIAL OFFICER | Form 4 sale | 43,253 | $1.1M | 24.4% | Plan not stated | SEC |
| Dec 16, 2019 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 25,000 | $584k | 53.7% | Unusual | SEC |
| Nov 19, 2019 | Thero John F | President and CEO | Form 4 sale | 274,454 | $6.2M | 10.5% | Plan not stated | SEC |
| Nov 12, 2019 | Ekman Lars | Director | Form 4 sale | 38,600 | $747k | 100.0% | Unusual | SEC |
| Nov 11, 2019 | Thero John F | President and CEO | Form 4 sale | 475,546 | $8.1M | 15.4% | Plan not stated | SEC |
| Nov 5, 2019 | Ekman Lars | Director | Form 4 sale | 6,400 | $115k | 100.0% | Unusual | SEC |
| Sep 3, 2019 | Ekman Lars | Director | Form 4 sale | 91,016 | $1.4M | 100.0% | Unusual | SEC |
| Jul 11, 2019 | Stack David M | Director | Form 4 sale | 51,991 | $1.2M | 100.0% | Unusual | SEC |
| Jul 5, 2019 | Zakrzewski Joseph S | Director | Form 4 sale | 100,000 | $2.4M | 54.2% | Unusual | SEC |
| Jul 3, 2019 | Berg Aaron | CHIEF COMMERCIAL OFFICER | Form 4 sale | 98,814 | $2.1M | 73.1% | Unusual | SEC |
| Jul 1, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 54,186 | $1.1M | 63.4% | Unusual | SEC |
| Jul 1, 2019 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 50,000 | $984k | 70.6% | Unusual | SEC |
| Jun 24, 2019 | Berg Aaron | CHIEF COMMERCIAL OFFICER | Form 4 sale | 113,195 | $2.1M | 75.7% | Unusual | SEC |
| Jun 18, 2019 | Zakrzewski Joseph S | Director | Form 4 sale | 100,000 | $1.9M | 54.2% | Unusual | SEC |
| May 31, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 27,229 | $488k | 46.6% | Unusual | SEC |
| May 29, 2019 | Stack David M | Director | Form 4 sale | 33,799 | $624k | 100.0% | Unusual | SEC |
| May 17, 2019 | Stack David M | Director | Form 4 sale | 13,174 | $237k | 100.0% | Unusual | SEC |
| Apr 30, 2019 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 9,541 | $178k | 2.6% | Plan not stated | SEC |
| Apr 30, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 27,230 | $509k | 46.6% | Unusual | SEC |
| Apr 1, 2019 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 9,542 | $191k | 2.6% | Plan not stated | SEC |
| Apr 1, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 53,060 | $1.1M | 62.1% | Unusual | SEC |
| Mar 4, 2019 | Thero John F | President and CEO | Form 4 sale | 250,000 | $5.3M | 10.7% | Plan not stated | SEC |
| Mar 4, 2019 | Ekman Lars | Director | Form 4 sale | 135,377 | $2.9M | 100.0% | Unusual | SEC |
| Mar 1, 2019 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 55,543 | $1.2M | 13.5% | Plan not stated | SEC |
| Mar 1, 2019 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 100,000 | $2.2M | 83.0% | Unusual | SEC |
| Feb 28, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 27,231 | $564k | 46.6% | Unusual | SEC |
| Feb 22, 2019 | Zakrzewski Joseph S | Director | Form 4 sale | 180,625 | $3.6M | 68.1% | Unusual | SEC |
| Feb 22, 2019 | Van Heek G Jan | Director | Form 4 sale | 203,382 | $4.1M | 93.5% | Unusual | SEC |
| Feb 22, 2019 | Peterson Kristine | Director | Form 4 sale | 163,500 | $3.3M | 100.0% | Unusual | SEC |
| Feb 22, 2019 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 50,000 | $949k | 70.9% | Unusual | SEC |
| Feb 15, 2019 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 25,000 | $439k | 54.9% | Unusual | SEC |
| Feb 1, 2019 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 37,530 | $644k | 9.6% | Plan not stated | SEC |
| Jan 31, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 42,624 | $745k | 57.7% | Unusual | SEC |
| Jan 24, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 1M | $18.5M | 100.0% | Unusual | SEC |
| Jan 11, 2019 | Kennedy Joseph T | General Counsel | Form 4 sale | 3,173 | $60k | 1.4% | Plan not stated | SEC |
| Jan 10, 2019 | Zakrzewski Joseph S | Director | Form 4 sale | 200,000 | $3.4M | 70.3% | Unusual | SEC |
| Jan 10, 2019 | Stack David M | Director | Form 4 sale | 125,504 | $2.3M | 100.0% | Unusual | SEC |
| Jan 10, 2019 | Ekman Lars | Director | Form 4 sale | 140,416 | $2.4M | 100.0% | Unusual | SEC |
| Jan 9, 2019 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 200,000 | $3.1M | 92.0% | Unusual | SEC |
| Jan 2, 2019 | Zakrzewski Joseph S | Director | Form 4 sale | 526,500 | $6.9M | 86.2% | Unusual | SEC |
| Dec 31, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 26,943 | $363k | 11.0% | Plan not stated | SEC |
| Dec 31, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 17,041 | $230k | 4.8% | Plan not stated | SEC |
| Nov 30, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 17,042 | $303k | 4.8% | Plan not stated | SEC |
| Nov 30, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 23,306 | $415k | 9.7% | Plan not stated | SEC |
| Nov 12, 2018 | Thero John F | President and CEO | Form 4 sale | 607,611 | $11.6M | 22.5% | Plan not stated | SEC |
| Oct 31, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 17,042 | $353k | 4.8% | Plan not stated | SEC |
| Oct 31, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 23,307 | $483k | 9.7% | Plan not stated | SEC |
| Oct 1, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 316,604 | $5.1M | 48.1% | Unusual | SEC |
| Oct 1, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 50,249 | $845k | 18.7% | Plan not stated | SEC |
| Sep 25, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 879,241 | $9.8M | 72.0% | Unusual | SEC |
| Sep 24, 2018 | Zakrzewski Joseph S | Director | Form 4 sale | 500,000 | $5.3M | 68.9% | Unusual | SEC |
| Sep 24, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 1.1M | $11.4M | 83.2% | Unusual | SEC |
| Sep 24, 2018 | Kalb Michael Wayne | SVP and CFO | Form 4 sale | 150,000 | $1.6M | 90.9% | Unusual | SEC |
| Jul 2, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 26,942 | $81k | 59.4% | Unusual | SEC |
| Apr 3, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 26,942 | $78k | 59.4% | Unusual | SEC |
| Jan 31, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 44,857 | $167k | 70.9% | Unusual | SEC |
| Jan 23, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 135,205 | $596k | 48.8% | Unusual | SEC |
| Jan 17, 2018 | Kennedy Joseph T | General Counsel | Form 4 sale | 51,106 | $209k | 100.0% | Unusual | SEC |
| Jan 11, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 2,612 | $11k | 1.8% | Plan not stated | SEC |
| Jan 5, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 64,683 | $285k | 31.3% | Unusual | SEC |
| Jan 2, 2018 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 128,257 | $545k | 47.5% | Unusual | SEC |
| Oct 5, 2017 | Ketchum Steven B | Chief Scientific Officer | Form 4 sale | 63,479 | $221k | 30.9% | Unusual | SEC |
| Jul 3, 2017 | Kennedy Joseph T | General Counsel | Form 4 sale | 307,911 | $1.2M | 100.0% | Unusual | SEC |
| Nov 9, 2016 | Kennedy Joseph T | General Counsel | Form 4 sale | 122,358 | $372k | 43.0% | Unusual | SEC |
| Oct 1, 2012 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 150,000 | $1.9M | 57.3% | Unusual | SEC |
| Sep 4, 2012 | Gordon Carl L | Director | Form 4 sale | 233,700 | $3.4M | 97.6% | Unusual | SEC |
| Sep 4, 2012 | OrbiMed Capital GP III LLC | Director | Form 4 sale | 233,700 | $3.4M | 97.6% | Unusual | SEC |
| Jul 27, 2012 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 150,000 | $2.1M | 57.3% | Unusual | SEC |
| Jul 27, 2012 | Thero John F | President | Form 4 sale | 300,926 | $4.3M | 97.0% | Unusual | SEC |
| Jul 27, 2012 | Kennedy Joseph T | Senior VP and General Counsel | Form 4 sale | 6,950 | $96k | 100.0% | Unusual | SEC |
| Jul 27, 2012 | Huff Paul | Chief Commercial Officer | Form 4 sale | 6,950 | $96k | 100.0% | Unusual | SEC |
| Jul 27, 2012 | Sedlack Stuart D | Senior Vice President | Form 4 sale | 6,950 | $96k | 100.0% | Unusual | SEC |
| Jul 27, 2012 | Gordon Carl L | Director | Form 4 sale | 366,300 | $5.4M | 97.9% | Unusual | SEC |
| Jul 27, 2012 | Isaly Samuel D | Director | Form 4 sale | 366,300 | $5.4M | 97.9% | Unusual | SEC |
| Jun 27, 2012 | Huff Paul | Chief Commercial Officer | Form 4 sale | 50,000 | $749k | 100.0% | Unusual | SEC |
| Jun 19, 2012 | Gordon Carl L | Director | Form 4 sale | 617,100 | $8M | 98.2% | Unusual | SEC |
| Jun 19, 2012 | Orbimed Advisors LLC | Director | Form 4 sale | 617,100 | $8M | 98.2% | Unusual | SEC |
| Jun 18, 2012 | Huff Paul | Chief Commercial Officer | Form 4 sale | 163,025 | $2M | 100.0% | Unusual | SEC |
| Jun 7, 2012 | Huff Paul | Chief Commercial Officer | Form 4 sale | 16,725 | $202k | 100.0% | Unusual | SEC |
| May 29, 2012 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 150,000 | $1.8M | 65.6% | Unusual | SEC |
| Apr 19, 2012 | Abingworth LLP | 10% owner | Form 4 sale | 4M | $38.5M | 71.5% | Unusual | SEC |
| Apr 9, 2012 | Thero John F | President | Form 4 sale | 150,926 | $1.5M | 100.0% | Unusual | SEC |
| Apr 3, 2012 | Abingworth LLP | 10% owner | Form 4 sale | 2.3M | $25.3M | 29.1% | Unusual | SEC |
| Apr 3, 2012 | Healy James | Director | Form 4 sale | 2M | $22M | 26.6% | Unusual | SEC |
| Mar 29, 2012 | Healy James | Director | Form 4 sale | 1M | $11M | 11.7% | Plan not stated | SEC |
| Mar 23, 2012 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 160,000 | $1.9M | 67.1% | Unusual | SEC |
| May 2, 2011 | Isaly Samuel D | Director | Form 4 sale | 132,900 | $2.1M | 88.5% | Unusual | SEC |
| May 2, 2011 | Gordon Carl L | Director | Form 4 sale | 132,900 | $2.1M | 88.5% | Unusual | SEC |
| Apr 25, 2011 | Van Heek G Jan | Director | Form 4 sale | 30,000 | $497k | 64.8% | Unusual | SEC |
| Apr 21, 2011 | Gordon Carl L | Director | Form 4 sale | 750,000 | $12.5M | 97.6% | Unusual | SEC |
| Apr 21, 2011 | OrbiMed Capital GP III LLC | Director | Form 4 sale | 750,000 | $12.5M | 97.6% | Unusual | SEC |
| Apr 20, 2011 | Ahlholm Frederick W | Vice President Finance | Form 4 sale | 31,250 | $496k | 100.0% | Unusual | SEC |
| Apr 20, 2011 | Gordon Carl L | Director | Form 4 sale | 3.8M | $58.2M | 99.3% | Unusual | SEC |
| Apr 20, 2011 | Isaly Samuel D | Director | Form 4 sale | 3.8M | $58.2M | 99.3% | Unusual | SEC |
| Apr 19, 2011 | Soni Paresh | SVP and Head of Development | Form 4 sale | 80,000 | $1.2M | 100.0% | Unusual | SEC |
| Apr 18, 2011 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 300,000 | $4.7M | 82.5% | Unusual | SEC |
| Apr 18, 2011 | Van Heek G Jan | Director | Form 4 sale | 3,000 | $50k | 13.4% | Plan not stated | SEC |
| Apr 18, 2011 | Abingworth LLP | 10% owner | Form 4 sale | 4.2M | $62.1M | 34.6% | Unusual | SEC |
| Apr 4, 2011 | Ahlholm Frederick W | Vice President Finance | Form 4 sale | 31,250 | $234k | 100.0% | Unusual | SEC |
| Mar 29, 2011 | Healy James | Director, 10% owner | Form 4 sale | 424,900 | $3.1M | 4.8% | Plan not stated | SEC |
| Mar 28, 2011 | Gordon Carl L | Director | Form 4 sale | 173,000 | $1.3M | 73.8% | Unusual | SEC |
| Mar 28, 2011 | Orbimed Advisors LLC | Director | Form 4 sale | 173,000 | $1.3M | 73.8% | Unusual | SEC |
| Mar 25, 2011 | Healy James | Director, 10% owner | Form 4 sale | 575,100 | $4.3M | 6.0% | Plan not stated | SEC |
| Mar 21, 2011 | Gordon Carl L | Director | Form 4 sale | 77,000 | $543k | 55.0% | Unusual | SEC |
| Mar 21, 2011 | Orbimed Advisors LLC | Director | Form 4 sale | 77,000 | $543k | 55.0% | Unusual | SEC |
| Mar 15, 2011 | Gordon Carl L | Director | Form 4 sale | 225,000 | $1.7M | 77.9% | Unusual | SEC |
| Mar 15, 2011 | OrbiMed Capital GP III LLC | Director | Form 4 sale | 225,000 | $1.7M | 77.9% | Unusual | SEC |
| Mar 11, 2011 | Abingworth LLP | 10% owner | Form 4 sale | 2.8M | $20.6M | 18.5% | Unusual | SEC |
| Mar 11, 2011 | Buatois Eric | 10% owner | Form 4 sale | 2M | $15M | 17.4% | Plan not stated | SEC |
| Mar 10, 2011 | Sofinnova Venture Partners Vii L P | 10% owner | Form 4 sale | 637,000 | $4.6M | 5.2% | Plan not stated | SEC |
| Mar 8, 2011 | Abingworth LLP | 10% owner | Form 4 sale | 550,000 | $4.1M | 3.6% | Plan not stated | SEC |
| Mar 7, 2011 | Gordon Carl L | Director | Form 4 sale | 75,000 | $574k | 53.2% | Unusual | SEC |
| Mar 7, 2011 | OrbiMed Capital GP III LLC | Director | Form 4 sale | 75,000 | $574k | 53.2% | Unusual | SEC |
| Mar 4, 2011 | Abingworth LLP | 10% owner | Form 4 sale | 100,000 | $760k | 0.6% | Plan not stated | SEC |
| Mar 2, 2011 | Abingworth LLP | 10% owner | Form 4 sale | 1.2M | $9.2M | 7.2% | Plan not stated | SEC |
| Mar 2, 2011 | OrbiMed Capital GP III LLC | Director | Form 4 sale | 245,000 | $1.9M | 78.6% | Unusual | SEC |
| Mar 2, 2011 | Gordon Carl L | Director | Form 4 sale | 245,000 | $1.9M | 78.6% | Unusual | SEC |
| Mar 1, 2011 | Abingworth LLP | 10% owner | Form 4 sale | 325,000 | $2.6M | 1.9% | Plan not stated | SEC |
| Feb 25, 2011 | Sofinnova Management VII, L.L.C. | 10% owner | Form 4 sale | 363,000 | $3M | 2.9% | Plan not stated | SEC |
| Feb 25, 2011 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 60,000 | $490k | 52.8% | Unusual | SEC |
| Feb 22, 2011 | Zakrzewski Joseph S | Chief Executive Officer | Form 4 sale | 100,000 | $854k | 65.1% | Unusual | SEC |
| Feb 22, 2011 | Soni Paresh | SVP and Head of Development | Form 4 sale | 120,000 | $1M | 100.0% | Unusual | SEC |